Cumulative drug approval applications under priority review
STO-REC-STATT2T18JT1 Official
496
China · end of 2024
Cumulative drug approval applications under priority review in China stood at 496 at end of 2024 (State Council).
- Publisher
- State Council
- Authority tier
- T1 Official
- Locator
- Measures facilitate approval of 48 first-in-class innovative drugs
- Retrieved
- 17 Sep 2026
- Status
- Verified
What the source says
Since China updated its drug registration and administrative rules in 2020, 496 drug approval applications have been placed under the priority review program, with 42.54 percent treating cancer.
Verbatim extraction verified: The figure 496 is directly attested in the quoted passage (Measures facilitate approval of 48 first-in-class innovative drugs).
The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.
- APA
- State Council of China. (2024). Measures facilitate approval of 48 first-in-class innovative drugs. Retrieved September 17, 2026, from https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Via StatOrigin, https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX
- MLA
- State Council of China. "Measures facilitate approval of 48 first-in-class innovative drugs." 2024, https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX.
- Chicago
- State Council of China. "Measures facilitate approval of 48 first-in-class innovative drugs." 2024. https://english.www.gov.cn/news/202503/20/content_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX.
- BibTeX
- @misc{statecouncil2024cumulative0hd2xx, author = {{State Council of China}}, title = {Measures facilitate approval of 48 first-in-class innovative drugs}, year = {2024}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX}, note = {Original source: https://english.www.gov.cn/news/202503/20/content\_WS67db7e91c6d0868f4e8f0fd6.html. Accessed September 17, 2026.} }
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Chain of Custody · Verification Audit
Primary Source
- Publisher
- State Council of China · homepage ↗
- Authority tier
- Tier 1 · Multilateral Official
- Report
- Measures facilitate approval of 48 first-in-class innovative drugs
- Type
- Press release
- Published
- —
- Locator
- Measures facilitate approval of 48 first-in-class innovative drugs
- Retrieved
- 17 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification & Integrity
- Audit status
- Verified
- Review protocol
- Editorial review
- Checked on
- 17 September 2026
- Last revision
- 17 September 2026
- Archival URI
- /stat/stat_T2T18J6M9Z7TJ6G9BJNS0HD2XX